Seeking Alpha

Bryan Boulden's  Instablog

Bryan Boulden
Send Message
I am a part time investor focused on building my family's wealth incrementally over the long term by investing in companies that are well positioned to benefit from important macroeconomic themes. I have a passion for research and hold a Master's Degree in Integrated Science from the University... More
  • Gilead's Pipeline Continues To Flow 0 comments
    May 14, 2014 7:56 AM | about stocks: GILD

    In a recent article I made the case that Gilead Science (NASDAQ:GILD) is perhaps one of the best investment opportunities in the S&P 500. The company's impressive pipeline boasts 10 drugs currently in Phase 3 clinical trials or awaiting final regulatory approval. As the article was published, Gilead announced promising results of a Phase 2 clinical trial involving a new application of its drug Anexa in combination with Sanofi's Mulitaq. As I mentioned in the article, neither this newly announced potential drug combination or any of the drugs currently in Gilead's pipeline will generate the revenue or earnings of Sovaldi. Yet taken together, Gilead's robust pipeline and continued innovation will help to diversify and grow the company's overall portfolio of products.

    Disclosure: I am long GILD.

    Themes: Biotech Stocks: GILD
Back To Bryan Boulden's Instablog HomePage »

Instablogs are blogs which are instantly set up and networked within the Seeking Alpha community. Instablog posts are not selected, edited or screened by Seeking Alpha editors, in contrast to contributors' articles.

Comments (0)
Track new comments
Be the first to comment
Full index of posts »
Latest Followers

StockTalks

More »
Posts by Themes
Instablogs are Seeking Alpha's free blogging platform customized for finance, with instant set up and exposure to millions of readers interested in the financial markets. Publish your own instablog in minutes.